Elephant in the Room-Reference-Cited by-同舟云学术

Elephant in the Room

Published:2018-01 Issue:1 Volume:11 Page:
ISSN:1941-7713
Container-title:Circulation: Cardiovascular Quality and Outcomes
language:en
Short-container-title:Circ Cardiovasc Qual Outcomes

Author:

Jackevicius Cynthia A.¹

Affiliation:

1. From the Department of Pharmacy Practice and Administration, College of Pharmacy, Western University of Health Sciences, Pomona, CA; Institute for Clinical Evaluative Sciences, Toronto, Canada; Veterans Affairs Greater Los Angeles Healthcare System, CA; Institute of Health Policy, Management and Evaluation, Faculty of Medicine, University of Toronto, Canada); and University Health Network, Toronto, Canada.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference13 articles.

1. Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers

2. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy

3. Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy

4. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers

5. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges and Potential Improvements to Patient Access to Pharmaceuticals;Circulation;2020-08-25

2. Just Price for PCSK9 Inhibitors: No less, No More;Journal of the American Heart Association;2018-11-06

3. Prior authorisation for PCSK9 inhibitors raises concerns;PharmacoEconomics & Outcomes News;2018-01